
Crescent Biopharma reports Q2 2026 results, advances cancer drug trials, and raises $143.7M to fund operations through 2028
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...


